A retrospective analysis evaluated the efficacy and safety of ixazomib maintenance therapy after autologous stem cell transplantation in 28 patients with multiple myeloma in China. The median age of the patients was 57 years (range 48–69). Before transplantation, 32.1% of patients achieved a complete response, 25% a very good partial response, and 42.9% a partial response; this improved to 60.7% complete response after transplantation. After maintenance treatment with ixazomib, 53.5% of patients had a complete response, 28.6% a very good partial response, and 17.9% a partial response; progression occurred in 4 patients. Estimated 3-year progression-free survival was 70.8% and overall survival was 87.4%. Patients with negative minimal residual disease for more than 1 year had a 3-year progression-free survival of 100%. The incidence of grade 3 and higher adverse effects was 3.6%.